Episode 3: Opeyemi Olabisi on APOL1-Mediated Kidney Disease and Community Engagement
We talk with Dr. Opeyemi Olabisi, MD, PhD, about the history and future of APOL1-mediated FSGS, the role of clinical researchers in building trust with patients, his innovative CARE and JUSTICE programs to bring kidney health screenings and research opportunities to the underrepresented African American community, and why his expertise as an MD/PhD in molecular biology led him to also become a leader in community engagement. The JAK-STAT pathway gets some love as well!
Dr. Olabisi's research and publications: https://medicine.duke.edu/profile/opeyemi-olabisi
More information on the CARE and JUSTICE studies: https://kidneycareandjustice.com/
Disclosures: Dr. Olabisi reports receiving research funding from NIH and Icagen, and consulting for Maze Therapeutics and Podium Bio.
Dr. Olabisi's research and publications: https://medicine.duke.edu/profile/opeyemi-olabisi
More information on the CARE and JUSTICE studies: https://kidneycareandjustice.com/
Disclosures: Dr. Olabisi reports receiving research funding from NIH and Icagen, and consulting for Maze Therapeutics and Podium Bio.
Creators and Guests
Host
Kenar Jhaveri
Chair, ISGD Education Committee. Nephrologist Educator, Rapidly Progressive Glomerular Nephrologist, onconephrologist, cyclist 🚴♀️, runner 🏃 Editor in chief: ASN Kidney News
Host
Koyal Jain
ISGD Education Committee Co-Chair | PD @UNCkidney | Director of UME @UNCDeptMedicine | Glomerular Diseases and Vasculitis | Medical Education | Tweets are my own
Guest
Opeyemi Olabisi
Duke Physician-Scientist, Nephrologist whose Lab focuses on APOL1 research and podocyte biology.